Clinical imaging factors of excellent outcome after thrombolysis in large-vessel stroke: a THRACE subgroup analysis

Nolwenn Riou-Comte, Benjamin Gory, Marc Soudant, François Zhu, Yu Xie, Lisa Humbertjean, Gioia Mione, Catherine Oppenheim, Francis Guillemin, Serge Bracard, Sébastien Richard, THRACE investigators, Nolwenn Riou-Comte, Benjamin Gory, Marc Soudant, François Zhu, Yu Xie, Lisa Humbertjean, Gioia Mione, Catherine Oppenheim, Francis Guillemin, Serge Bracard, Sébastien Richard, THRACE investigators

Abstract

Background: For patients with stroke with large-vessel occlusion (LVO), study of factors predicting response to intravenous thrombolysis (IVT) would allow identifying subgroups with high expected gain, and those for whom it could be considered as futile, and even detrimental. From patients included in the Mechanical Thrombectomy After Intravenous Alteplase vs Alteplase Alone After Stroke trial, we investigated clinical-imaging factors associated with optimal response to IVT.

Methods: We included patients receiving IVT alone. Excellent outcome was defined by a 3-month modified Rankin Scale (mRS) score ≤1. Clinical-imaging predictors were assessed on multivariate analysis after multiple imputations. The predictive performance of the model was assessed with the C-statistic.

Results: Among 247 patients with LVO treated with IVT alone, 77 (31%) showed 3-month mRS ≤1. Predictors of 3-month mRS ≤1 were no medical history of hypertension (OR 2.43; 95% CI 1.74 to 3.38; p=0.007); no current smoking (OR 2.76; 95% CI 1.79 to 4.26; p=0.02); onset-to-IVT time (OR 0.47 per hour increase; 95% CI 0.23 to 0.78; p=0.003); diffusion-weighted imaging (DWI) volume (OR 0.78 per 10 mL increase; 95% CI 0.68 to 0.89; p=0.0004); presence of susceptibility vessel sign (SVS) (OR 7.89; 95% CI 1.65 to 37.78; p=0.01) and SVS length (OR 0.87 per mm increase; 95% CI 0.80 to 0.94; p=0.001). The prediction models showed a C-statistic=0.79 (95% CI 0.79 to 0.80).

Conclusions: In patients with stroke with anterior-circulation LVO treated with IVT alone, predictors of excellent outcome at 3 months were no medical history of hypertension or current smoking, reduced onset-to-IVT time, small DWI volume, presence of SVS and short SVS length. These predictive factors could help practitioners in decision-making for IVT implementation in reperfusion strategies, all the more for the drip and ship paradigm.

Trial registration number: NCT01062698.

Keywords: stroke; thrombectomy; thrombolysis.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart. Excellent outcome was defined as a 3-month modified Rankin Scale (mRS) score ≤1. *One of the requirements for mechanical thrombectomy was the absence of neurological improvement ≥4 points between baseline National Institutes of Health Stroke Scale (NIHSS) and NIHSS within 1 hour of IVT. ICA, internal carotid artery occlusion; IVT, intravenous thrombolysis; MT, mechanical thrombectomy; THRACE, Mechanical Thrombectomy After Intravenous Alteplase vs Alteplase Alone After Stroke.

References

    1. Seners P, Turc G, Maïer B. Incidence and predictors of early recanalization after intravenous thrombolysis: a systematic review and meta-analysis. Stroke 2016;47:2409–12. 10.1161/STROKEAHA.116.014181
    1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group . Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–8. 10.1056/NEJM199512143332401
    1. Hacke W, Kaste M, Bluhmki E, et al. . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29. 10.1056/NEJMoa0804656
    1. Berge E, Whiteley W, Audebert H, et al. . European stroke organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021;6:I–LXII. 10.1177/2396987321989865
    1. Turc G, Apoil M, Naggara O, et al. . Magnetic resonance Imaging-DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke. Stroke 2013;44:1323–8. 10.1161/STROKEAHA.111.000127
    1. Baek JH, Kim K, Lee Y-B, et al. . Predicting stroke outcome using clinical- versus imaging-based scoring system. J Stroke Cerebrovasc Dis 2015;24:642–8. 10.1016/j.jstrokecerebrovasdis.2014.10.009
    1. Hernández-Pérez M, Pérez de la Ossa N, Aleu A, et al. . Natural history of acute stroke due to occlusion of the middle cerebral artery and intracranial internal carotid artery. J Neuroimaging 2014;24:354–8. 10.1111/jon.12062
    1. Bracard S, Ducrocq X, Mas JL, et al. . Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016;15:1138–47. 10.1016/S1474-4422(16)30177-6
    1. Legrand L, Tisserand M, Turc G, et al. . Fluid-Attenuated inversion recovery vascular Hyperintensities-Diffusion-Weighted imaging mismatch identifies acute stroke patients most likely to benefit from recanalization. Stroke 2016;47:424–7. 10.1161/STROKEAHA.115.010999
    1. Nave AH, Kufner A, Bücke P, et al. . Hyperintense vessels, collateralization, and functional outcome in patients with stroke receiving endovascular treatment. Stroke 2018;49:675–81. 10.1161/STROKEAHA.117.019588
    1. Balucani C, Levine SR, Khoury JC, et al. . Acute ischemic stroke with very early clinical improvement: a national Institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke trials exploratory analysis. J Stroke Cerebrovasc Dis 2016;25:894–901. 10.1016/j.jstrokecerebrovasdis.2015.10.028
    1. Grotta JC, Welch KM, Fagan SC, et al. . Clinical deterioration following improvement in the NINDS rt-PA stroke trial. Stroke 2001;32:661–8. 10.1161/01.STR.32.3.661
    1. Wahlgren N, Ahmed N, Dávalos A, et al. . Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in Stroke-Monitoring study (SITS-MOST): an observational study. Lancet 2007;369:275–82. 10.1016/S0140-6736(07)60149-4
    1. Shuaib A, Butcher K, Mohammad AA, et al. . Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 2011;10:909–21. 10.1016/S1474-4422(11)70195-8
    1. Béjot Y, Jacquin A, Daubail B, et al. . Smoking status and severity of ischemic stroke. A population-based study. Eur Neurol 2014;71:59–64. 10.1159/000355021
    1. Chan S-L, Sweet JG, Bishop N, et al. . Pial collateral reactivity during hypertension and aging: understanding the function of collaterals for stroke therapy. Stroke 2016;47:1618–25. 10.1161/STROKEAHA.116.013392
    1. Barrett KM, Ding YH, Wagner DP, et al. . Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the acute stroke accurate prediction (ASAP) trial serial imaging substudy. Stroke 2009;40:2422–7. 10.1161/STROKEAHA.109.548933
    1. Gautheron V, Xie Y, Tisserand M, et al. . Outcome after reperfusion therapies in patients with large baseline diffusion-weighted imaging stroke lesions: a THRACE trial (mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke) subgroup analysis. Stroke 2018;49:750–3. 10.1161/STROKEAHA.117.020244
    1. Humpich M, Singer OC, du Mesnil de Rochemont R, et al. . Effect of early and delayed recanalization on infarct pattern in proximal middle cerebral artery occlusion. Cerebrovasc Dis 2006;22:51–6. 10.1159/000092338
    1. Riedel CH, Zimmermann P, Jensen-Kondering U, et al. . The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011;42:1775–7. 10.1161/STROKEAHA.110.609693
    1. Choi MH, Park GH, Lee JS, et al. . Erythrocyte fraction within retrieved thrombi contributes to thrombolytic response in acute ischemic stroke. Stroke 2018;49:652–9. 10.1161/STROKEAHA.117.019138
    1. Fonarow GC, Zhao X, Smith EE, et al. . Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311:1632–40. 10.1001/jama.2014.3203
    1. Rha J-H, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–73. 10.1161/01.STR.0000258112.14918.24
    1. Khatri P, Neff J, Broderick JP, et al. . Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005;36:2400–3. 10.1161/01.STR.0000185698.45720.58
    1. Zaidat OO, Yoo AJ, Khatri P, et al. . Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013;44:2650–63. 10.1161/STROKEAHA.113.001972
    1. Eilaghi A, Brooks J, d'Esterre C, et al. . Reperfusion is a stronger predictor of good clinical outcome than recanalization in ischemic stroke. Radiology 2013;269:240–8. 10.1148/radiol.13122327
    1. Takagi T, Kato T, Sakai H, et al. . Early neurologic improvement based on the National Institutes of health stroke scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy. J Stroke Cerebrovasc Dis 2014;23:69–74. 10.1016/j.jstrokecerebrovasdis.2012.09.013
    1. Yang P, Zhang Y, Zhang L, et al. . Endovascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med 2020;382:1981–93. 10.1056/NEJMoa2001123
    1. Zi W, Qiu Z, Li F, et al. . Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial. JAMA 2021;325:234–43. 10.1001/jama.2020.23523
    1. Suzuki K, Matsumaru Y, Takeuchi M, et al. . Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the SKIP randomized clinical trial. JAMA 2021;325:244–53. 10.1001/jama.2020.23522
    1. Dong Y, Han Y, Shen H, et al. . Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis. Stroke Vasc Neurol 2020;5:348–52. 10.1136/svn-2020-000388
    1. Campbell BCV, Mitchell PJ, Churilov L, et al. . Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018;378:1573–82. 10.1056/NEJMoa1716405
    1. Renaud L, Lebozec K, Voors-Pette C, et al. . Population pharmacokinetic/pharmacodynamic modeling of Glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen-induced platelet aggregation. J Clin Pharmacol 2020;60:1198–208. 10.1002/jcph.1616

Source: PubMed

3
구독하다